caa a22 4500 606158278 CHVBK 20210128100618.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10557-015-6571-z doi (NATIONALLICENCE)springer-10.1007/s10557-015-6571-z ATM Protein Kinase Signaling, Type 2 Diabetes and Cardiovascular Disease [Elektronische Daten] [Yolandi Espach, Amanda Lochner, Hans Strijdom, Barbara Huisamen] The ataxia-telangiectasia mutated (ATM) protein kinase is well known to play a significant role in the response to double stranded DNA breaks in the nucleus. Recently, it has become apparent that ATM is also involved in a large number of cytoplasmic processes and responses, some of which may contribute to metabolic and cardiovascular complications when disrupted. Due to its involvement in these processes, therapeutic activation of ATM could potentially be a novel approach for the prevention or treatment of cardiovascular disease. However, relatively little is currently known about the cardiovascular role of ATM. In this review, we highlight studies that have shed some light on the role of ATM in the cardiovascular context, namely in oxidative stress, atherosclerosis and metabolism, insulin resistance and cardiac remodeling. Springer Science+Business Media New York, 2015 Cardiovascular disease nationallicence Insulin resistance nationallicence Ataxia telangiectasia nationallicence Oxidative stress nationallicence Type 2 diabetes nationallicence Espach Yolandi Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut Lochner Amanda Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut Strijdom Hans Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut Huisamen Barbara Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/1(2015-02-01), 51-58 0920-3206 29:1<51 2015 29 10557 https://doi.org/10.1007/s10557-015-6571-z text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6571-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Espach Yolandi Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut NATIONALLICENCE 700 1- Lochner Amanda Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut NATIONALLICENCE 700 1- Strijdom Hans Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut NATIONALLICENCE 700 1- Huisamen Barbara Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/1(2015-02-01), 51-58 0920-3206 29:1<51 2015 29 10557